VEGFA and neoplasm: Renal cell carcinoma (RCC) was the first human tumour in which inhibition of angiogenesis, mediated by bevacizumab, a monoclonal antibody (mAb)-neutralising vascular endothelial growth factor (VEGF), showed clinical benefit (Yang et al, 2003a).